1087 related articles for article (PubMed ID: 32259782)
1. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
2. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
6. Single peptides and combination modalities for triple negative breast cancer.
Razazan A; Behravan J
J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibodies for Triple Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
[TBL] [Abstract][Full Text] [Related]
8. The role of immune checkpoint inhibition in triple negative breast cancer.
Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
Heeke AL; Tan AR
Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Singh S; Numan A; Maddiboyina B; Arora S; Riadi Y; Md S; Alhakamy NA; Kesharwani P
Drug Discov Today; 2021 Jul; 26(7):1721-1727. PubMed ID: 33745879
[TBL] [Abstract][Full Text] [Related]
12. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.
Jarroudi OA; Bairi KE; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():29-62. PubMed ID: 38175341
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.
Poddar A; Rao SR; Prithviraj P; Kannourakis G; Jayachandran A
Curr Oncol; 2022 Sep; 29(10):6847-6863. PubMed ID: 36290817
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer.
Michel LL; von Au A; Mavratzas A; Smetanay K; Schütz F; Schneeweiss A
Target Oncol; 2020 Aug; 15(4):415-428. PubMed ID: 32514907
[TBL] [Abstract][Full Text] [Related]
17. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
18. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Dermime S; Merhi M; Merghoub T
Front Immunol; 2021; 12():781872. PubMed ID: 34745152
[No Abstract] [Full Text] [Related]
[Next] [New Search]